Sam Brusco, Associate Editor09.21.22
Ivory Graft Ltd. has gained CE mark approval for the Ivory Dentin Graft, a new dentin graft.
The graft material is tailored for dental procedures based on autologous dentin grafts. The active organic matrix retains the natural form of sourced porcine dentin, as well as the protein matrix.
According to the company, the dentin graft substitute was clinically proven to support new hard tissue formation. A study compared Ivory Dentin Graft subjects and those grafted with a porcine cortico-cancellous heterologous bone mix for alveolar ridge preservation after tooth extraction.
At four months after the procedure, efficacy showed “superior promoting of good interface between the host bone and graft material” with 85% vs. 40% efficacy, as well as 50% more increase in new bone formation (60.75% vs. 42.81%).
Both features are crucial to tissue regeneration and integration following tooth extraction and grafting, and facilitate osteogenic activity.
"We believe that Ivory Graft's patented technology for this new category of dentin grafts has the potential to revolutionize dental graft substitutes and clinical grafting materials in general," CEO Eyal Miller told the press. "We look forward to exhibiting and meeting with leading clinicians at the European Congress of Osseointegration (EAO) in Geneva next week and invite you to visit our booth (D47). Ivory Graft has shifted phase from R&D to commercialization, and partnered with expert European commercial partners, to accelerate Ivory Dentin Graft's presence in the EU. We are currently in the final phases of establishing our Distributing Partners and Key Opinion Leaders' network, with world leading professionals."
The graft material is tailored for dental procedures based on autologous dentin grafts. The active organic matrix retains the natural form of sourced porcine dentin, as well as the protein matrix.
According to the company, the dentin graft substitute was clinically proven to support new hard tissue formation. A study compared Ivory Dentin Graft subjects and those grafted with a porcine cortico-cancellous heterologous bone mix for alveolar ridge preservation after tooth extraction.
At four months after the procedure, efficacy showed “superior promoting of good interface between the host bone and graft material” with 85% vs. 40% efficacy, as well as 50% more increase in new bone formation (60.75% vs. 42.81%).
Both features are crucial to tissue regeneration and integration following tooth extraction and grafting, and facilitate osteogenic activity.
"We believe that Ivory Graft's patented technology for this new category of dentin grafts has the potential to revolutionize dental graft substitutes and clinical grafting materials in general," CEO Eyal Miller told the press. "We look forward to exhibiting and meeting with leading clinicians at the European Congress of Osseointegration (EAO) in Geneva next week and invite you to visit our booth (D47). Ivory Graft has shifted phase from R&D to commercialization, and partnered with expert European commercial partners, to accelerate Ivory Dentin Graft's presence in the EU. We are currently in the final phases of establishing our Distributing Partners and Key Opinion Leaders' network, with world leading professionals."